title: 28th Annual JPMorgan Healthcare Conference--Forest Laboratories and Icagen.
abstract: The JPMorgan Healthcare conference, held in San Francisco, included presentations by various pharmaceutical companies summarizing their achievements in 2009 and expectations for 2010. This conference report highlights presentations from Forest Laboratories Inc and Icagen Inc. Investigational drugs from Forest Laboratories, including roflumilast (in collaboration with Nycomed Inc/Mitsubishi Tanabe Pharma Corp), ceftaroline fosamil (with AstraZeneca plc), linaclotide (with Ironwood Pharmaceuticals Inc/Astellas Pharma Inc/Almirall Prodesfarma SA), cariprazine (with Gedeon Richter Ltd/Mitsubishi Tanabe Pharma Corp), aclidinium bromide (with Almirall), dutogliptin (with Phenomix Corp/Chiesi Farmaceutici SpA) and levomilnacipran (with Pierre Fabre SA), and from Icagen, including ICA-105665, are discussed.
authors.affiliation: Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. sophie.gale@thomsonreuters.com
authors.forename: Sophie
authors.initials: S
authors.lastname: Gale
authors.forename: Gary
authors.initials: G
authors.lastname: Croasdell
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D026902:Potassium Channel Blockers / Q000627:therapeutic use; D019141:Respiratory System Agents / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D014150:Antipsychotic Agents; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D026902:Potassium Channel Blockers; D019141:Respiratory System Agents